The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.
Glynn Weldon Gilcrease
No relevant relationships to disclose
John R. Weis
No relevant relationships to disclose
Kimberly Jones
No relevant relationships to disclose
Thaylon Davis
No relevant relationships to disclose
Marlene Mitchell
No relevant relationships to disclose
Cynthia Davidson
No relevant relationships to disclose
Sunil Sharma
Consultant or Advisory Role - Novartis (U)
Honoraria - Novartis
Research Funding - Novartis